Literature DB >> 12851771

[When is a urodynamic investigation indicated for overactive bladder?].

S Schumacher1.   

Abstract

Overactive bladder (OAB) is generally not disease specific. Symptoms are frequency, nocturia, and urgency with or without urge incontinence. The prevalence of 16.6%, evaluated in six European countries, is surprisingly high. Causes for overactive bladder are an increase of sensory stimulation and/or a decrease of sensory threshold of the bladder or a disproportion between strength of afferent stimulation and central inhibition of micturition reflex resulting in detrusor overactivity. Overactive bladder is a symptom-based diagnosis. Urodynamics is an important diagnostic tool in daily routine. Urodynamics encompasses a spectrum of different techniques and is more than just cystometry. Simple cystometry or video cystometry should be carried out after evaluation with a frequency volume chart, flow rates, and residuals, mostly by ultrasound. Urodynamic observations should never be discussed separately but always together with history, symptoms, signs, and pathological findings. It is not necessary to perform a filling and voiding cystometry in each patient with symptoms and signs of overactive bladder. Indications for cystometry are prior to invasive therapy or where previous medical or surgical therapy has failed, after pelvic surgery or pelvic irradiation, in patients with signs or symptoms suggestive of an emptying disorder, in neurological disorders, or where there is any doubt about the diagnosis. Diagnostic evaluation of geriatric patients with overactive bladder can usually be accomplished with a basic assessment while invasive procedures should be the exception.

Entities:  

Mesh:

Year:  2003        PMID: 12851771     DOI: 10.1007/s00120-003-0361-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  Difficult to manage patient populations--mixed symptomatology.

Authors:  W Artibani
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

2.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

3.  Clinical aspects of the overactive bladder and detrusor overactivity.

Authors:  S Garnett; P Abrams
Journal:  Scand J Urol Nephrol Suppl       Date:  2002

4.  How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study.

Authors:  I Milsom; P Abrams; L Cardozo; R G Roberts; J Thüroff; A J Wein
Journal:  BJU Int       Date:  2001-06       Impact factor: 5.588

Review 5.  Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder.

Authors:  A W Thomas; P Abrams
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

6.  Geriatric considerations in the diagnosis and management of overactive bladder.

Authors:  Joseph G Ouslander
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

7.  Role of cystometry in evaluating patients with overactive bladder.

Authors:  Adam J Flisser; Jerry G Blaivas
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

Review 8.  Are urodynamic tests useful tools for the initial conservative management of non-neurogenic urinary incontinence? A review of the literature.

Authors:  Enrico Colli; Walter Artibani; John Goka; Fabio Parazzini; Alan J Wein
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

  8 in total
  2 in total

Review 1.  [Dynamic bladder neck stenosis as a cause of psychogenic mictrition discomforts and mictrition disorders].

Authors:  E-A Günthert
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

Review 2.  [Chronic pollakiuria: cystectomy or psychotherapy].

Authors:  A Kuffel; K P Kapitza; B Löwe; E Eichelberg; A Gumz
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.